Search Results

You are looking at 31 - 40 of 96 items for :

  • "skin cancer" x
Clear All
Full access

Hamdy A. Azim, Abdul-Rahman Jazieh and Mohammad Jahanzeb

, and Australia, people have a higher risk of developing skin cancer because they have fair skin, a characteristic that is uncommonly witnessed in other regions. Although guidelines for prevention and early detection of skin cancer are needed in these

Full access

.2016.0064 Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology Bichakjian Christopher K. MD Olencki Thomas DO Aasi Sumaira Z. MD Alam Murad MD, MSCI Andersen James S. MD Berg Daniel MD

Full access

Patrick Ross Jr

oncology for airway malignancies, Barrett’s esophagus with high-grade dysplasia, and nonmelanoma skin cancer. In addition, PDT has been used in the laboratory and in some investigational clinical settings for high-grade gliomas, oral and laryngeal lesions

Full access

.2014.0190 Optimal Treatment of Unresectable Nonmelanoma Skin Cancers Olencki Thomas DO 05 2014 12 12 5S 5S 789 789 792 792 0120789 10.6004/jnccn.2014.0191 Targeted Agents: Management of Dermatologic Toxicities Burtness Barbara MD 05

Full access

Klippel Zandra K. e MD Chao Chun c PhD 10 2018 16 16 10 10 1201 1201 1208 1208 10.6004/jnccn.2018.7051 jnccn_16_10_009 Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer Centers Mori Shoko a BS

Full access

Tella Sri Harsha a b * MBBS Appiah Adams Kusi c PhD Smith Lynette c PhD Ganti Apar Kishor d MD 11 03 2019 17 17 3 3 229 229 236 236 jnccn18096 10.6004/jnccn.2018.7086 Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously

Full access

) Utah Crisis of Standards 2010 Influenza Pandemic Algorithm Visitor Policy Letter (Huntsman Cancer Institute) Treatment of Cancer by Site Breast Cancer Colorectal Cancer Melanoma Non-Melanoma Skin Cancer Prostate Cancer T-Cell and Primary Cutaneous

Full access

Optimal Treatment of Unresectable Nonmelanoma Skin Cancers Targeted Agents: Management of Dermatologic Toxicities Supporters: Breast Cancer Supported by educational grants from AstraZeneca; Eisai Inc.; Genentech; and Novartis Oncology

Full access

Nikki Tang and Desiree Ratner

and medical procedures while minimizing the impact on their quality of life. RT is contraindicated as neoadjuvant therapy in patients with a hereditary predisposition to skin cancer, making Hh inhibitors a reasonable alternative. Patients who are

Full access

Barbara Burtness

complication with BRAF inhibitors is the development of new skin cancers, such as eruptive squamous cell carcinomas. 5 “We need to be aggressive about managing these skin cancers with resection and close follow-up,” she recommended. Figure 2 Skin